Terumo BCT, Inc.

Terumo BCT, Inc. is a medical technology company headquartered in Lakewood, Colorado. Founded as COBE Laboratories in 1964, it is a subsidiary of the Tokyo-based global medical technology firm, Terumo Corporation (TSE: 4543), which acquired the company in 2011. Terumo BCT employs approximately 7,900 people globally, with about 2,000 in Colorado. Its parent company, Terumo Corporation, has over 30,000 employees worldwide and reported annual revenues in the range of $6 to $7 billion in recent fiscal years.

As a global leader in blood and cell-based technologies, Terumo BCT develops and manufactures products, software, and services for blood centers, hospitals, and research organizations. The company's major product lines include automated systems for blood component collection (Trima Accel), therapeutic apheresis and cell collection (Spectra Optia), automated blood processing (Reveos), pathogen reduction technologies, and cell expansion systems for cell and gene therapies (Quantum Flex). The company's offerings are used for blood transfusions, plasma collections, and the manufacturing of advanced cell and gene therapies.

Terumo BCT is an active two-way litigant, appearing in the provided case list as both a plaintiff and a defendant. With three plaintiff suits and two defendant suits, its patent litigation posture is that of an operating company engaged in disputes with a competitor, rather than a non-practicing entity (NPE) or a purely defensive litigant. All five of its tracked cases are against Haemonetics Corporation, a direct competitor in the blood technology market. The litigation, initiated in 2025, includes patent infringement suits filed by Haemonetics in the U.S. District Court for the District of Colorado and multiple challenges filed by Terumo BCT against Haemonetics' patents at the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB).